These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33245987)

  • 21. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX
    Turner BM; Gimenez-Sanders MA; Soukiazian A; Breaux AC; Skinner K; Shayne M; Soukiazian N; Ling M; Hicks DG
    Cancer Med; 2019 Aug; 8(9):4176-4188. PubMed ID: 31199586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
    Chaudhary LN; Jawa Z; Szabo A; Visotcky A; Chitambar CR
    Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):48-54. PubMed ID: 26808222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation oncotype DX
    Lashen A; Toss MS; Fadhil W; Oni G; Madhusudan S; Rakha E
    Histopathology; 2023 Apr; 82(5):755-766. PubMed ID: 36631400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
    Farrugia DJ; Landmann A; Zhu L; Diego EJ; Johnson RR; Bonaventura M; Soran A; Dabbs DJ; Clark BZ; Puhalla SL; Jankowitz RC; Brufsky AM; Lembersky BC; Ahrendt GM; McAuliffe PF; Bhargava R
    Mod Pathol; 2017 Aug; 30(8):1078-1085. PubMed ID: 28548119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologist's health-care value in the triage of Oncotype DX
    Dabbs DJ; Clark BZ; Serdy K; Onisko A; Brufsky AM; Smalley S; Perkins S; Bhargava R
    Histopathology; 2018 Oct; 73(4):692-700. PubMed ID: 29920746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.
    Wang J; Chen H; Koenig J; Wu Y; Bedrosian I; Arun B; Ding Q; Khazai L; Resetkova E; Huo L; Sneige N; Albarracin C
    Breast Cancer Res Treat; 2024 Jan; 203(1):73-83. PubMed ID: 37751078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of PONDx, a prospective multicenter study of the Oncotype DX
    Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
    Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Story of the Magee Equations: The Ultimate in Applied Immunohistochemistry.
    Bhargava R; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2023 Aug; 31(7):490-499. PubMed ID: 36165933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of Oncotype Dx recurrence score using clinical parameters: A comparison of available tools and a simple predictor based on grade and progesterone receptor.
    Thibodeau S; Voutsadakis IA
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):89-96. PubMed ID: 30796885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
    Felts JL; Zhu J; Han B; Smith SJ; Truica CI
    Breast J; 2017 Nov; 23(6):677-686. PubMed ID: 28097781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
    Stemmer SM; Klang SH; Ben-Baruch N; Geffen DB; Steiner M; Soussan-Gutman L; Merling S; Svedman C; Rizel S; Lieberman N
    Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
    Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
    Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
    Bernhardt SM; Dasari P; Wrin J; Raymond W; Edwards S; Walsh D; Townsend AR; Price TJ; Ingman WV
    Breast Cancer Res; 2020 Aug; 22(1):90. PubMed ID: 32811558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Orucevic A; Bell JL; McNabb AP; Heidel RE
    Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.